Skip to content
Search

Latest Stories

'Closure of Lloyds Pharmacy branches will wake-up ministers to reality of funding crisis faced by community pharmacy'

Lloyds Pharmacy’s closure of all its 1,300 branches will wake-up the ministers and NHS officials to the reality of community pharmacy sector in England has reached crisis point, expressed Nigel Swift Managing Director of Rowlands pharmacy and Deputy Managing Director of PHOENIX UK.

On Friday, The SUN reported that the UK’s second largest pharmacy provider - is allegedly in the process of selling its entire estate of 1300 branches. Lloyds Pharmacy will no longer be a High Street presence following its decision to put all its pharmacy branches at the risk of closure. In January it has announced to close its 237 Sainsbury-based pharmacies.


However, a spokesperson for LloydsPharmacy has confirmed with Pharmacy Business that except its stores in Sainsbury's, no other LloydsPharmacy store is at risk of closure.

“LloydsPharmacy is reviewing its community pharmacy estate and is selectively selling some branches. No LloydsPharmacy store is at risk of closure, except those within the Sainsbury’s estate."

“The majority of buyers of these selected branches are independent pharmacy owners and local businesspeople who have demonstrated that they are committed to our branch teams and patients, and are well placed to meet the ongoing health needs of the local community.

“The LloydsPharmacy team is pleased that its colleagues from these stores will be joining successful, local businesses and that for patients there will be no change in the way they use their local pharmacy.”

Nigel highlighted the fact that community pharmacy is struggling due to insufficient government funding and immense pressures on GPs and A&E departments – an ongoing issue which poses a very real threat to the sector.

Commenting on the announcement, he said: “It’s not just Lloyds – an independent analysis by Ernst & Young estimated that 75% of community pharmacies will be in financial distress in the coming years. £750 million has been taken out of the English contract due to inflation since it began."

“We have seen hundreds of random closures in recent years – and more will follow - which has resulted in people having less access to essential NHS care, support and advice. That lack of access then piles additional pressures on GPs and A&E departments which are already struggling to cope with patient demand. This makes no sense.”

“The governments in Scotland and Wales are investing in community pharmacy because they understand how that benefits patients and the NHS overall. Yet in England, Ministers are saying they want pharmacy to do more with no new funding at a time when prescription volumes are growing. This is economically illiterate hence the understandable decision by Lloyds pharmacy – which made a £66m loss last year despite Covid-related support - to exit the UK High Street.”

“The English Health Minister talks about implementing a “pharmacy first” approach to relieve pressures on GPs and A&E departments. That cannot be delivered through a network which clearly is under-funded and in decline. Not all 1300 Lloyds pharmacies will close: some will be bought but the trend is clear: fewer pharmacies, less patient access and more pressure on other parts of the NHS. Now more than ever before we need government in England to engage with us, recognise there is a patient care crisis and agree a way forward.”

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less